Clinical Trial

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
Protocol Amendment History 1 change
notable Trial sites expanded: 11 -> 16 locations 2026-05-28
Trial Details
NCT Number NCT07228247
Lead Sponsor Hutchmed
Conditions Solid Tumors, Adult
Enrollment 147 participants
Start Date 2025-12-16
Primary Completion 2028-11-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-07